If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Summary'Other Hematological Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Hematological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Hematological Disorders. Other Hematological Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Other Hematological Disorders.- A review of the Other Hematological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Other Hematological Disorders pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Other Hematological Disorders.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Other Hematological Disorders pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of ContentsTable of Contents 2List of Tables 4List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Other Hematological Disorders Overview 7Therapeutics Development 8An Overview of Pipeline Products for Other Hematological Disorders 8Other Hematological Disorders Therapeutics under Development by Companies 10Other Hematological Disorders Therapeutics under Investigation by Universities/Institutes 11Late Stage Products 12Comparative Analysis 12Mid Clinical Stage Products 13Comparative Analysis 13Early Clinical Stage Products 14Comparative Analysis 14Discovery and Pre-Clinical Stage Products 15Comparative Analysis 15Other Hematological Disorders Therapeutics – Products under Development by Companies 16Other Hematological Disorders Therapeutics – Products under Investigation by Universities/Institutes 17Companies Involved in Other Hematological Disorders Therapeutics Development 18Mitsubishi Tanabe Pharma Corporation 18Regado Biosciences. 19Embryome Sciences, Inc. 20Other Hematological Disorders – Therapeutics Assessment 21Assessment by Monotherapy Products 21Assessment by Combination Products 22Assessment by Route of Administration 23Assessment by Molecule Type 25Drug Profiles 28REG-Anti Platelet Program - Drug Profile 28Product Description 28Mechanism of Action 28R&D Progress 28GB-1057 - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29nitric oxide - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30rituximab - Drug Profile 31Product Description 31Mechanism of Action 31R&D Progress 31carvedilol - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33vinblastine sulfate + methotrexate + 6-mercaptopurine - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34REG-3 - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35Vascular Program - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36Interleukin-7 - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38Erythropoietin Encoding mRNA - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39Other Hematological Disorders Therapeutics – Drug Profile Updates 40Other Hematological Disorders Therapeutics - Dormant Products 41Other Hematological Disorders – Product Development Milestones 42Featured News & Press Releases 42Jul 07, 2011: CorMedix Submits Design Dossier For Neutrolin To Start European Approval Process 42Jun 29, 2011: Kyowa Hakko Kirin Initiates Phase III Clinical Study Of KW-3357 In Japan 42Jun 01, 2011: S*BIO's SB1518 Alleviates MF-Associated Splenomegaly And Shows No Myelosuppression And No Exacerbation Of Cytopenias 43Jan 31, 2011: AMT Receives EUR1.1 Million Funding For Acute Intermittent Porphyria Gene Therapy 43Jan 19, 2011: Geron Initiates Phase II Clinical Trial Of Imetelstat In Patients With Essential Thrombocythemia 44Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure 45Jun 16, 2010: Relypsa Initiates Open-Label Phase II Clinical Study Of RLY5016 For Management Of Hyperkalemia 45Jun 02, 2010: Alexion Accelerates Plans To Launch Soliris In Japan 46Jun 01, 2010: LLS And Onconova Form Partnership To Advance Clinical Development Of ESTYBON In High Risk MDS Patients 46Apr 20, 2010: Alexion Completes Enrollment in All Four Clinical Trials of Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) 47Appendix 48Methodology 48Coverage 48Secondary Research 48Primary Research 48Expert Panel Validation 48Contact Us 49Disclaimer 49List of TablesNumber of Products Under Development for Other Hematological Disorders, H1 2013 8Products under Development for Other Hematological Disorders – Comparative Analysis, H1 2013 9Number of Products under Development by Companies, H1 2013 10Number of Products under Investigation by Universities/Institutes, H1 2013 11Comparative Analysis by Late Stage Development, H1 2013 12Comparative Analysis by Mid Clinical Stage Development, H1 2013 13Comparative Analysis by Early Clinical Stage Development, H1 2013 14Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 15Products under Development by Companies, H1 2013 16Products under Investigation by Universities/Institutes, H1 2013 17Mitsubishi Tanabe Pharma Corporation, H1 2013 18Regado Biosciences., H1 2013 19Embryome Sciences, Inc., H1 2013 20Assessment by Monotherapy Products, H1 2013 21Assessment by Combination Products, H1 2013 22Assessment by Stage and Route of Administration, H1 2013 24Assessment by Stage and Molecule Type, H1 2013 27Other Hematological Disorders Therapeutics – Drug Profile Updates 40Other Hematological Disorders Therapeutics – Dormant Products 41List of FiguresNumber of Products under Development for Other Hematological Disorders, H1 2013 8Products under Development for Other Hematological Disorders – Comparative Analysis, H1 2013 9Products under Development by Companies, H1 2013 10Products under Investigation by Universities/Institutes, H1 2013 11Late Stage Products, H1 2013 12Mid Clinical Stage Products, H1 2013 13Early Clinical Stage Products, H1 2013 14Discovery and Pre-Clinical Stage Products, H1 2013 15Assessment by Monotherapy Products, H1 2013 21Assessment by Combination Products, H1 2013 22Assessment by Route of Administration, H1 2013 23Assessment by Stage and Route of Administration, H1 2013 24Assessment by Molecule Type, H1 2013 25Assessment by Stage and Molecule Type, H1 2013 26